• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Shields Health Solutions is acquiring ExceleraRx


The new company will serve 60 health systems.

Shields Health Solutions is acquiring ExceleraRx, the companies announced today.

The combined entity will be a specialty pharmacy powerhouse that will serve more 60 health systems and academic medical centers and 700 hospitals that “account for the opportunity of $30 billion in specialty pharmacy revenue,” says the press release about the acquisition.

“On-site, integrated specialty pharmacy is the future of complex patient care and we look forward to combining forces with Excelera to make our impact even greater. As we have shown, this model materially improves clinical outcomes for patients and reduces total medical expenses for covered patients,” said Lee Cooper, the CEO of Shields, said in a press release.

“Shields and Excelera have a shared vision for enabling fully integrated, on-site care for patients with complex, chronic diseases by promoting cross-industry collaboration and best practice sharing,” Troy Polan, acting CEO at Excelera, said in the prepared announcement.

“Shields has been a leader of the evolving specialty pharmacy industry since the company’s inception eight years ago,” said Jack Shields, founder and chairman of Shields, in the press release. “Our acquisition of Excelera will expand our health system footprint, enhance our data and technology platform, and uniquely position Shields to spur growth in the $100 billion-plus specialty pharmacy market.”

The use of specialty medications to treat patients with multiple, chronic illnesses or rare, hard-to-treat diseases is increasing an average of 17% per year, and health systems across the U.S. have been building on-site, integrated specialty pharmacies to provide comprehensive, streamlined care for this growing group of patients.

Since 2015, the prevalence of health system-owned specialty pharmacies in large hospitals has doubled, with nearly 90% of large hospitals operating a specialty pharmacy in 2019, the press release said.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.